Cidara's U.S. Commercial Partner, Melinta Therapeutics, has Initiated Commercial Launch of REZZAYO™ EMA Regulatory Decision for Rezafungin Expected by Year End 2023 SAN DIEGO, July 31, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced an update on REZZAYO™ (rezafungin for injection) which was approved by the U.S. Food and Drug Administration (FDA) earlier this…
wpengineJuly 31, 2023